Federation des caisses Desjardins du Quebec’s Gyre Therapeutics GYRE Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-75	Closed	-$908	–	2702
2024 Q4	$908	Buy	+75	New	+$960	﹤0.01%	2332
2021 Q3	–	Sell	-150	Closed	-$4.87K	–	2580
2021 Q2	$4.87K	Hold	150	–	–	﹤0.01%	2246
2021 Q1	$5.67K	Hold	150	–	–	﹤0.01%	2164
2020 Q4	$7.1K	Buy	+150	New	+$6.5K	﹤0.01%	1986

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's GYRE Position: Q1 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Gyre Therapeutics (GYRE) in Q1 2025, closing a stake of 75 shares — an estimated $908 sold.

Federation des caisses Desjardins du Quebec first reported a position in GYRE in Q4 2020 and held it in 4 quarters. The position peaked at $7.1K in Q4 2020. 46 funds tracked by Wall St. Rank hold GYRE as of Q1 2025.

Federation des caisses Desjardins du Quebec reported no remaining Gyre Therapeutics position as of Q1 2025 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 75 Gyre Therapeutics shares in Q1 2025, an estimated $908.
Federation des caisses Desjardins du Quebec first reported a position in Gyre Therapeutics in Q4 2020 and held it in 4 quarters.
Federation des caisses Desjardins du Quebec's Gyre Therapeutics position peaked at $7.1K in Q4 2020.
46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2025, filed 15 May 2025.